disitamab
Start here
At ESMO 2026, RemeGen presented three studies of its HER2-directed antibody-drug conjugate disitamab vedotin, spanning advanced extramammary Paget's disease, neoadjuvant treatment of muscle-invasive bladder cancer, and HER2 testing in bladder carcinoma in situ. The most detailed results come from the Formula-10 study in advanced EMPD: of 25 patients meeting radiographic evaluation criteria, the objective response rate was 88% and the disease control rate 100%, with a median progression-free survival of 14.23 months. Grade 3 or higher treatment-related adverse events occurred in 29.6% of patients. Detailed findings from the neoadjuvant MIBC and bladder CIS HER2 testing studies have not been reported in this coverage.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comESMO 2026 Roundup: Three Disitamab Vedotin Studies in Advanced EMPD, Neoadjuvant MIBC and Bladder CIS HER2 Testing
RemeGen presented three studies of disitamab vedotin at ESMO 2026, covering advanced EMPD, neoadjuvant treatment of MIBC, and HER2 testing in bladder CIS. In the Formula-10 study, 25 patients met the radiographic evaluation criteria, with an ORR of 88%, a DCR of 100%, median PFS of 14.23 months, and grade 3 or higher treatment-related adverse events in 29.6%.
Heat trend for this story
Heat now 11·Peak in the comparable set 13 (Oct 26 11:00)·Change over 24h in the comparable set +115%·Participants now 2
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.